Germany Passes Healthcare Cost-Cutting Reforms as Pharma Industry Warns of Investment Impact

Germany’s healthcare system overhaul introduces billions in savings measures while increasing pressure on pharmaceutical companies.

German lawmakers have approved a major healthcare cost-reduction package aimed at addressing the country’s growing budget pressures, introducing measures that will significantly increase financial contributions from the pharmaceutical industry.

The reforms, approved by Germany’s federal and state governments, are designed to reduce healthcare spending by €16.3 billion ($18.6 billion) as the country faces a projected budget shortfall of more than €40 billion ($45.8 billion) by 2030.

While the measures are intended to improve the sustainability of Germany’s statutory health insurance system, they have faced strong opposition from pharmaceutical companies, with several major drugmakers warning that the changes could affect future investment in the country.

Germany Healthcare Reform Targets Pharmaceutical Spending

A central part of the legislation is a significant increase in mandatory pharmaceutical rebates paid by drug manufacturers.

The reforms will:

• Increase the legally required pharmaceutical rebate from 7% to 15.5%

• Introduce an additional 9% rebate on patented vaccines

• Freeze vaccine prices until 2030

• Limit hospital cost increases until 2029

• Increase healthcare co-payments for some services
  

According to the German Bundestag, the pharmaceutical rebate increase is intended to ensure that the industry makes a direct contribution towards controlling healthcare expenditure.

The final legislation represents a compromise compared with earlier proposals that would have introduced a dynamic rebate system linked to overall pharmaceutical spending and healthcare system revenues.

Drugmakers had criticised the original approach, arguing that variable rebates would make financial planning and investment decisions more difficult.

Government Says Reform Is Necessary to Control Healthcare Costs

German Health Minister Nina Warken said the reforms were necessary given the scale of the country’s financial challenge.

“With necessary savings of almost €19 billion in the coming year alone, it is clear that there will be noticeable changes and that this law will demand something from everyone,” Warken said.

The German government argues that the measures are required to protect the long-term sustainability of the statutory health insurance system, which provides coverage for the majority of the country’s population.

However, pharmaceutical companies have warned that increased cost pressures could impact research investment, manufacturing expansion and the availability of innovative medicines.

Pharmaceutical Industry Pushes Back Against German Healthcare Changes

The reforms have received strong criticism from pharmaceutical leaders, who argue that Germany risks becoming a less attractive location for investment.

Several major pharmaceutical companies raised concerns after the healthcare overhaul was initially proposed earlier in 2026.

Pfizer Raises Investment Concerns

Pfizer CEO Albert Bourla warned German Chancellor Friedrich Merz that the reforms could damage Germany’s attractiveness as a destination for pharmaceutical investment.

Bourla also withdrew from an international investor conference in Germany following the announcement of the proposals.

Roche Reviews Future Investment Plans

Roche Pharma CEO Daniel Steiners also said the company would reassess future investment decisions in Germany due to concerns over the changing healthcare environment.

Eli Lilly Reduces Manufacturing Investment

Eli Lilly reduced its planned investment in a manufacturing facility in Rhineland-Palatinate.

The company cut the planned spending on the site, which was intended to support production of its weight-loss medicines, from approximately €2.3 billion ($2.7 billion).

Boehringer Ingelheim Scales Back Spending

German pharmaceutical company Boehringer Ingelheim also reduced planned investment in its domestic operations, cancelling more than €900 million ($1 billion) in planned expenditure.

US Government Reviews German Drug Pricing Policies

The healthcare reforms have also attracted attention beyond Germany.

The US government launched an investigation into Germany’s pharmaceutical pricing policies, examining whether what it described as persistent underpayment for innovative medicines could represent an unreasonable or discriminatory burden on US pharmaceutical companies.

The review reflects broader international tensions around medicine pricing, with governments attempting to control healthcare costs while pharmaceutical companies argue that lower reimbursement can affect innovation and investment.

What Germany’s Healthcare Reform Means for Pharma

Germany remains one of the world’s largest pharmaceutical markets, but the latest reforms highlight the growing challenge facing healthcare systems globally: balancing affordability with continued investment in innovation.

For pharmaceutical companies, the increased rebate requirements represent a direct reduction in potential revenue from the German market.

The industry will now be closely monitoring whether the reforms influence:

• future research and development investment

• manufacturing expansion decisions

• clinical trial activity

• availability of newly launched medicines
  

While Germany’s government views the changes as necessary cost controls, pharmaceutical companies argue that maintaining investment incentives will be critical to ensuring continued access to innovative therapies.

Summary

Germany has approved a major healthcare cost-saving package designed to reduce spending by €16.3 billion, including a significant increase in pharmaceutical rebates and new pricing restrictions.

The reforms increase the pharmaceutical rebate rate from 7% to 15.5% and introduce additional measures targeting healthcare expenditure.

While policymakers argue the changes are needed to strengthen the country’s healthcare system, major pharmaceutical companies including Pfizer, Roche, Eli Lilly and Boehringer Ingelheim have warned that the reforms could impact future investment decisions in Germany.

The legislation highlights the ongoing global debate between healthcare affordability and maintaining incentives for pharmaceutical innovation.

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com